Suma Krishnan - Feb 26, 2022 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
President, R&D, Director, 10%+ Owner
Signature
/s/ Suma Krishnan
Stock symbol
KRYS
Transactions as of
Feb 26, 2022
Transactions value $
-$205,125
Form type
4
Date filed
3/1/2022, 08:20 PM
Previous filing
Dec 14, 2021
Next filing
Aug 9, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Tax liability -$205K -3.28K -0.19% $62.50 1.75M Feb 26, 2022 Direct F1, F2
holding KRYS Common Stock 1.81M Feb 26, 2022 By Spouse F3
holding KRYS Common Stock 90K Feb 26, 2022 By SMK Trust
holding KRYS Common Stock 50K Feb 26, 2022 By Krishan Family Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRYS Stock Option (Right to Buy) Award $0 +50K $0.00 50K Feb 28, 2022 Common Stock 50K $63.55 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents tax withholding upon the vesting of 7,100 shares of restricted stock on February 26, 2022.
F2 The closing price on February 25, 2022 of the Company's common stock on NASDAQ.
F3 Directly beneficially owned by Krish S. Krishnan, the spouse of the reporting person.
F4 Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
F5 The option vests in four equal annual installments beginning on February 28, 2023.